MedTrace Logo

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-03-28

No results posted yet for this study

Summary

A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.

Conditions

Interventions

DRUG

CT-868 as SC Injection

CT-868

DRUG

Placebo as SC Injection

Placebo

DRUG

Active Comparator as SC Injection

Active Comparator

Sponsors & Collaborators

  • Carmot Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc., a member of the Roche Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-16
Primary Completion
2022-04-22
Completion
2022-04-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973111 on ClinicalTrials.gov